DanCann Pharma A/S: DanCann Pharma Announces Outcome of Directed Issues to Board and Management

The Directed Issues

The Board of Directors (the "Board") decided on 25 November 2024 to issue 2,250,000,000 shares and 1,125,000,000 warrants of series TO3, free of charge, to several external investors. The investors subscribed for all shares and warrants. In connection with this, the Board convened an Extraordinary General Meeting to be held on 10 December 2024 with proposals to issue shares and warrants to members of the Company's Board and management on the same terms, such members of the Company's Board and management to commit to subscribing for shares and warrants to express their long-term commitment to the Company.

On this basis the Extraordinary General Meeting would decide on Directed Issues of a maximum of 200,000,000 shares and a maximum of 100,000,000 warrants of series TO3 to board and management members Jeppe Krog Rasmussen, Carsten Trads, Jes Lunde and Christian Carlsen. On 10 December 2024, the Extraordinary General Meeting adopted the Directed Issues in accordance with the proposal. All shares and warrants have been subscribed for and allocated. The subscription price per newly issued share is DKK 0.002. The warrants are issued free of charge. Through the Directed Issues, the Company will initially raise approximately DKK 0.4 million before deduction of transaction costs.

Terms for warrants of series TO3

For every two shares subscribed for in the Directed Issues, one warrant is received free of charge. One warrant of series TO3 entitles the holder to subscribe for one new share in the Company. The subscription price per share shall correspond to DKK 0.0026. The subscription period takes place during the period from 12 January 2026 up to and including 1 February 2026. The warrants are issued free of charge and are not intended to be admitted to trading. A total of 100,000,000 warrants of series TO3 are issued in connection with the Directed Issues.

Shares, share capital, and dilution

The issue of the shares in the Directed Issues will result in the number of outstanding shares in the Company increasing by 200,000,000 from 3,791,101,234 to 3,991,101,234, and the share capital increasing by 200,000.00 DKK, from DKK 3,791,101.234 to DKK 3,991,101.234, resulting in a dilution effect of approximately 5.0 per cent.

In the event that all warrants of series TO3 are exercised, the number of outstanding shares will increase by an additional 100,000,000, and the share capital will increase by DKK 100,000.00. This will result in an additional dilution effect of approximately 2.4 per cent and a total dilution effect of approximately 7.3 per cent.

Advisors

Eminova Partners Corporate Finance AB act as financial advisor, and Nordic Issuing AB and Euronext Securities Copenhagen have been appointed as issuing agents, in connection with the Directed Issues. Mazanti-Andersen is legal advisor to DanCann Pharma in connection with the Directed Issues.

For further information regarding the Rights Issue, please contact:

Jeppe Krog Rasmussen, CEO

E-mail: jkr@dancann.com

About DanCann Pharma A/S

DanCann Pharma A/S (SS: DANCAN) was founded in 2018 and is a Danish biopharmaceutical Company powered by cannabinoids.

DanCann Pharma A/S (SS: DANCAN) is listed on the Spotlight Stock Market in Copenhagen/Stockholm.

For more information, visit: www.dancann.com

Forward-looking-statement:

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events, or developments that the Company believes, expects, or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology.

Forward-looking statements are subject to several risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, to obtain sufficient financing to execute the Company's business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company's research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities.

Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this presentation are made as of the date of this presentation and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.